ARTEMIS 011 Improves Osteosarcoma Progression Control

Company Hansoh Pharma; GSK Event Type Phase 3 full results Modality B7-H3-directed antibody-drug conjugate (topoisomerase-I payload) Asset Risvutatug rezetecan (HS-20093/GSK5764227) Target B7-H3 Disease Area Relapsed osteosarcoma Summary Hansoh disclosed full Phase III ARTEMIS-011 results on 27 October, following the 26 October ESMO presentation. In heavily…